Isis Pharmaceuticals, Inc. has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder. This is the ninth program to advance under the strategic alliance, which includes four drugs in development to treat neurological and neuromuscular disorders. To date, Isis has earned $329 million in payments from Biogen.    “Together with Biogen, we have made significant progress advancing multiple programs.  In our pip...